aluates Reports

$ 0.0

Automative

Global End-stage Renal Disease Therapeutics Market Research Report 2024

Published Date: November 2024

Report Code: QYRE-Auto-33Y18427

BUY CHAPTERS

Global End-stage Renal Disease Therapeutics Market Research Report 2024

Code: QYRE-Auto-33Y18427

Report

November 2024

Pages:95

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Fresenius

NIKKISO

B. Braun

Baxter

Asahi Kasei

Nipro

Weigao

Toray

Medtronic Inc

JMS Co Ltd

SB-KAWASUMI

Medica Group

Chongqing Shanwaishan

Amgen Inc

Deltanoid

AbbVie

Sanofi

Ardelyx Inc

Astrazeneca plc

Kyowa Hakko Kirin

End-stage Renal Disease Therapeutics Market Size

The global End-stage Renal Disease Therapeutics market was valued at US$ 7451 million in 2023 and is anticipated to reach US$ 11150 million by 2030, witnessing a CAGR of 6.1% during the forecast period 2024-2030.

End-stage Renal Disease Therapeutics Market

End-stage Renal Disease Therapeutics refers to a specialized range of medical treatments and medications aimed at managing chronic kidney disease as it progresses to advanced stages, particularly stages 4 and 5. These therapies are designed to slow further decline in kidney function, alleviate symptoms, improve quality of life, and prolong survival. Common treatments include hemodialysis, peritoneal dialysis, and kidney transplantation. In terms of medications, doctors may prescribe antihypertensive drugs, phosphate binders, and erythropoiesis-stimulating agents to manage associated complications, such as hypertension, anemia, and bone disorders in late-stage CKD patients.

North American market for End-stage Renal Disease Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for End-stage Renal Disease Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for End-stage Renal Disease Therapeutics in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of End-stage Renal Disease Therapeutics include Fresenius, Nikkiso, B.Braun, Baxter, Asahi Kasei, Nipro, Weigao, Toray, Medtronic, JMS, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for End-stage Renal Disease Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding End-stage Renal Disease Therapeutics.

The End-stage Renal Disease Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global End-stage Renal Disease Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the End-stage Renal Disease Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of End-stage Renal Disease Therapeutics Market Report

Report Metric	Details
Report Name	End-stage Renal Disease Therapeutics Market
Accounted market size in 2023	US$ 7451 million
Forecasted market size in 2030	US$ 11150 million
CAGR	6.1%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Drugs Device Other
Segment by Application	Hospital Dialysis Center Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Fresenius, Nikkiso, B.Braun, Baxter, Asahi Kasei, Nipro, Weigao, Toray, Medtronic, JMS, SB-KAWASUMI, Medica Group, Chongqing Shanwaishan, Amgen, Deltanoid, AbbVie, Sanofi, Ardelyx, AstraZeneca, Kyowa Hakko Kirin
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of End-stage Renal Disease Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is End-stage Renal Disease Therapeutics Market growing?

Ans: The End-stage Renal Disease Therapeutics Market witnessing a CAGR of 6.1% during the forecast period 2024-2030.

What is the End-stage Renal Disease Therapeutics Market size in 2030?

Ans: The End-stage Renal Disease Therapeutics Market size in 2030 will be US$ 11150 million.

Who are the main players in the End-stage Renal Disease Therapeutics Market report?

Ans: The main players in the End-stage Renal Disease Therapeutics Market are Fresenius, Nikkiso, B.Braun, Baxter, Asahi Kasei, Nipro, Weigao, Toray, Medtronic, JMS, SB-KAWASUMI, Medica Group, Chongqing Shanwaishan, Amgen, Deltanoid, AbbVie, Sanofi, Ardelyx, AstraZeneca, Kyowa Hakko Kirin

What are the Application segmentation covered in the End-stage Renal Disease Therapeutics Market report?

Ans: The Applications covered in the End-stage Renal Disease Therapeutics Market report are Hospital, Dialysis Center, Other

What are the Type segmentation covered in the End-stage Renal Disease Therapeutics Market report?

Ans: The Types covered in the End-stage Renal Disease Therapeutics Market report are Drugs, Device, Other

Recommended Reports

Kidney Disease Therapeutics

Renal Cancer & Fibrosis

Dialysis and Devices

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global End-stage Renal Disease Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Drugs

1.2.3 Device

1.2.4 Other

1.3 Market by Application

1.3.1 Global End-stage Renal Disease Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital

1.3.3 Dialysis Center

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global End-stage Renal Disease Therapeutics Market Perspective (2019-2030)

2.2 Global End-stage Renal Disease Therapeutics Growth Trends by Region

2.2.1 Global End-stage Renal Disease Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 End-stage Renal Disease Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 End-stage Renal Disease Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 End-stage Renal Disease Therapeutics Market Dynamics

2.3.1 End-stage Renal Disease Therapeutics Industry Trends

2.3.2 End-stage Renal Disease Therapeutics Market Drivers

2.3.3 End-stage Renal Disease Therapeutics Market Challenges

2.3.4 End-stage Renal Disease Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top End-stage Renal Disease Therapeutics Players by Revenue

3.1.1 Global Top End-stage Renal Disease Therapeutics Players by Revenue (2019-2024)

3.1.2 Global End-stage Renal Disease Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global End-stage Renal Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by End-stage Renal Disease Therapeutics Revenue

3.4 Global End-stage Renal Disease Therapeutics Market Concentration Ratio

3.4.1 Global End-stage Renal Disease Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by End-stage Renal Disease Therapeutics Revenue in 2023

3.5 Global Key Players of End-stage Renal Disease Therapeutics Head office and Area Served

3.6 Global Key Players of End-stage Renal Disease Therapeutics, Product and Application

3.7 Global Key Players of End-stage Renal Disease Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 End-stage Renal Disease Therapeutics Breakdown Data by Type

4.1 Global End-stage Renal Disease Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global End-stage Renal Disease Therapeutics Forecasted Market Size by Type (2025-2030)

5 End-stage Renal Disease Therapeutics Breakdown Data by Application

5.1 Global End-stage Renal Disease Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global End-stage Renal Disease Therapeutics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America End-stage Renal Disease Therapeutics Market Size (2019-2030)

6.2 North America End-stage Renal Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America End-stage Renal Disease Therapeutics Market Size by Country (2019-2024)

6.4 North America End-stage Renal Disease Therapeutics Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe End-stage Renal Disease Therapeutics Market Size (2019-2030)

7.2 Europe End-stage Renal Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe End-stage Renal Disease Therapeutics Market Size by Country (2019-2024)

7.4 Europe End-stage Renal Disease Therapeutics Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific End-stage Renal Disease Therapeutics Market Size (2019-2030)

8.2 Asia-Pacific End-stage Renal Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Asia-Pacific End-stage Renal Disease Therapeutics Market Size by Region (2019-2024)

8.4 Asia-Pacific End-stage Renal Disease Therapeutics Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America End-stage Renal Disease Therapeutics Market Size (2019-2030)

9.2 Latin America End-stage Renal Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America End-stage Renal Disease Therapeutics Market Size by Country (2019-2024)

9.4 Latin America End-stage Renal Disease Therapeutics Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa End-stage Renal Disease Therapeutics Market Size (2019-2030)

10.2 Middle East & Africa End-stage Renal Disease Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Country (2019-2024)

10.4 Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Fresenius

11.1.1 Fresenius Company Details

11.1.2 Fresenius Business Overview

11.1.3 Fresenius End-stage Renal Disease Therapeutics Introduction

11.1.4 Fresenius Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.1.5 Fresenius Recent Development

11.2 Nikkiso

11.2.1 Nikkiso Company Details

11.2.2 Nikkiso Business Overview

11.2.3 Nikkiso End-stage Renal Disease Therapeutics Introduction

11.2.4 Nikkiso Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.2.5 Nikkiso Recent Development

11.3 B.Braun

11.3.1 B.Braun Company Details

11.3.2 B.Braun Business Overview

11.3.3 B.Braun End-stage Renal Disease Therapeutics Introduction

11.3.4 B.Braun Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.3.5 B.Braun Recent Development

11.4 Baxter

11.4.1 Baxter Company Details

11.4.2 Baxter Business Overview

11.4.3 Baxter End-stage Renal Disease Therapeutics Introduction

11.4.4 Baxter Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.4.5 Baxter Recent Development

11.5 Asahi Kasei

11.5.1 Asahi Kasei Company Details

11.5.2 Asahi Kasei Business Overview

11.5.3 Asahi Kasei End-stage Renal Disease Therapeutics Introduction

11.5.4 Asahi Kasei Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.5.5 Asahi Kasei Recent Development

11.6 Nipro

11.6.1 Nipro Company Details

11.6.2 Nipro Business Overview

11.6.3 Nipro End-stage Renal Disease Therapeutics Introduction

11.6.4 Nipro Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.6.5 Nipro Recent Development

11.7 Weigao

11.7.1 Weigao Company Details

11.7.2 Weigao Business Overview

11.7.3 Weigao End-stage Renal Disease Therapeutics Introduction

11.7.4 Weigao Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.7.5 Weigao Recent Development

11.8 Toray

11.8.1 Toray Company Details

11.8.2 Toray Business Overview

11.8.3 Toray End-stage Renal Disease Therapeutics Introduction

11.8.4 Toray Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.8.5 Toray Recent Development

11.9 Medtronic

11.9.1 Medtronic Company Details

11.9.2 Medtronic Business Overview

11.9.3 Medtronic End-stage Renal Disease Therapeutics Introduction

11.9.4 Medtronic Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.9.5 Medtronic Recent Development

11.10 JMS

11.10.1 JMS Company Details

11.10.2 JMS Business Overview

11.10.3 JMS End-stage Renal Disease Therapeutics Introduction

11.10.4 JMS Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.10.5 JMS Recent Development

11.11 SB-KAWASUMI

11.11.1 SB-KAWASUMI Company Details

11.11.2 SB-KAWASUMI Business Overview

11.11.3 SB-KAWASUMI End-stage Renal Disease Therapeutics Introduction

11.11.4 SB-KAWASUMI Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.11.5 SB-KAWASUMI Recent Development

11.12 Medica Group

11.12.1 Medica Group Company Details

11.12.2 Medica Group Business Overview

11.12.3 Medica Group End-stage Renal Disease Therapeutics Introduction

11.12.4 Medica Group Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.12.5 Medica Group Recent Development

11.13 Chongqing Shanwaishan

11.13.1 Chongqing Shanwaishan Company Details

11.13.2 Chongqing Shanwaishan Business Overview

11.13.3 Chongqing Shanwaishan End-stage Renal Disease Therapeutics Introduction

11.13.4 Chongqing Shanwaishan Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.13.5 Chongqing Shanwaishan Recent Development

11.14 Amgen

11.14.1 Amgen Company Details

11.14.2 Amgen Business Overview

11.14.3 Amgen End-stage Renal Disease Therapeutics Introduction

11.14.4 Amgen Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.14.5 Amgen Recent Development

11.15 Deltanoid

11.15.1 Deltanoid Company Details

11.15.2 Deltanoid Business Overview

11.15.3 Deltanoid End-stage Renal Disease Therapeutics Introduction

11.15.4 Deltanoid Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.15.5 Deltanoid Recent Development

11.16 AbbVie

11.16.1 AbbVie Company Details

11.16.2 AbbVie Business Overview

11.16.3 AbbVie End-stage Renal Disease Therapeutics Introduction

11.16.4 AbbVie Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.16.5 AbbVie Recent Development

11.17 Sanofi

11.17.1 Sanofi Company Details

11.17.2 Sanofi Business Overview

11.17.3 Sanofi End-stage Renal Disease Therapeutics Introduction

11.17.4 Sanofi Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.17.5 Sanofi Recent Development

11.18 Ardelyx

11.18.1 Ardelyx Company Details

11.18.2 Ardelyx Business Overview

11.18.3 Ardelyx End-stage Renal Disease Therapeutics Introduction

11.18.4 Ardelyx Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.18.5 Ardelyx Recent Development

11.19 AstraZeneca

11.19.1 AstraZeneca Company Details

11.19.2 AstraZeneca Business Overview

11.19.3 AstraZeneca End-stage Renal Disease Therapeutics Introduction

11.19.4 AstraZeneca Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.19.5 AstraZeneca Recent Development

11.20 Kyowa Hakko Kirin

11.20.1 Kyowa Hakko Kirin Company Details

11.20.2 Kyowa Hakko Kirin Business Overview

11.20.3 Kyowa Hakko Kirin End-stage Renal Disease Therapeutics Introduction

11.20.4 Kyowa Hakko Kirin Revenue in End-stage Renal Disease Therapeutics Business (2019-2024)

11.20.5 Kyowa Hakko Kirin Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Fresenius

NIKKISO

B. Braun

Baxter

Asahi Kasei

Nipro

Weigao

Toray

Medtronic Inc

JMS Co Ltd

SB-KAWASUMI

Medica Group

Chongqing Shanwaishan

Amgen Inc

Deltanoid

AbbVie

Sanofi

Ardelyx Inc

Astrazeneca plc

Kyowa Hakko Kirin

List of Tables

Table 1. Global End-stage Renal Disease Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Drugs

Table 3. Key Players of Device

Table 4. Key Players of Other

Table 5. Global End-stage Renal Disease Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global End-stage Renal Disease Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global End-stage Renal Disease Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global End-stage Renal Disease Therapeutics Market Share by Region (2019-2024)

Table 9. Global End-stage Renal Disease Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global End-stage Renal Disease Therapeutics Market Share by Region (2025-2030)

Table 11. End-stage Renal Disease Therapeutics Market Trends

Table 12. End-stage Renal Disease Therapeutics Market Drivers

Table 13. End-stage Renal Disease Therapeutics Market Challenges

Table 14. End-stage Renal Disease Therapeutics Market Restraints

Table 15. Global End-stage Renal Disease Therapeutics Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global End-stage Renal Disease Therapeutics Market Share by Players (2019-2024)

Table 17. Global Top End-stage Renal Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in End-stage Renal Disease Therapeutics as of 2023)

Table 18. Ranking of Global Top End-stage Renal Disease Therapeutics Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by End-stage Renal Disease Therapeutics Revenue (CR5 and HHI) & (2019-2024)

Table 20. Global Key Players of End-stage Renal Disease Therapeutics, Headquarters and Area Served

Table 21. Global Key Players of End-stage Renal Disease Therapeutics, Product and Application

Table 22. Global Key Players of End-stage Renal Disease Therapeutics, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global End-stage Renal Disease Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global End-stage Renal Disease Therapeutics Revenue Market Share by Type (2019-2024)

Table 26. Global End-stage Renal Disease Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global End-stage Renal Disease Therapeutics Revenue Market Share by Type (2025-2030)

Table 28. Global End-stage Renal Disease Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global End-stage Renal Disease Therapeutics Revenue Market Share by Application (2019-2024)

Table 30. Global End-stage Renal Disease Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global End-stage Renal Disease Therapeutics Revenue Market Share by Application (2025-2030)

Table 32. North America End-stage Renal Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America End-stage Renal Disease Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America End-stage Renal Disease Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe End-stage Renal Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe End-stage Renal Disease Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe End-stage Renal Disease Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific End-stage Renal Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific End-stage Renal Disease Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific End-stage Renal Disease Therapeutics Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America End-stage Renal Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America End-stage Renal Disease Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America End-stage Renal Disease Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa End-stage Renal Disease Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa End-stage Renal Disease Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 47. Fresenius Company Details

Table 48. Fresenius Business Overview

Table 49. Fresenius End-stage Renal Disease Therapeutics Product

Table 50. Fresenius Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 51. Fresenius Recent Development

Table 52. Nikkiso Company Details

Table 53. Nikkiso Business Overview

Table 54. Nikkiso End-stage Renal Disease Therapeutics Product

Table 55. Nikkiso Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 56. Nikkiso Recent Development

Table 57. B.Braun Company Details

Table 58. B.Braun Business Overview

Table 59. B.Braun End-stage Renal Disease Therapeutics Product

Table 60. B.Braun Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 61. B.Braun Recent Development

Table 62. Baxter Company Details

Table 63. Baxter Business Overview

Table 64. Baxter End-stage Renal Disease Therapeutics Product

Table 65. Baxter Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 66. Baxter Recent Development

Table 67. Asahi Kasei Company Details

Table 68. Asahi Kasei Business Overview

Table 69. Asahi Kasei End-stage Renal Disease Therapeutics Product

Table 70. Asahi Kasei Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 71. Asahi Kasei Recent Development

Table 72. Nipro Company Details

Table 73. Nipro Business Overview

Table 74. Nipro End-stage Renal Disease Therapeutics Product

Table 75. Nipro Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 76. Nipro Recent Development

Table 77. Weigao Company Details

Table 78. Weigao Business Overview

Table 79. Weigao End-stage Renal Disease Therapeutics Product

Table 80. Weigao Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 81. Weigao Recent Development

Table 82. Toray Company Details

Table 83. Toray Business Overview

Table 84. Toray End-stage Renal Disease Therapeutics Product

Table 85. Toray Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 86. Toray Recent Development

Table 87. Medtronic Company Details

Table 88. Medtronic Business Overview

Table 89. Medtronic End-stage Renal Disease Therapeutics Product

Table 90. Medtronic Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 91. Medtronic Recent Development

Table 92. JMS Company Details

Table 93. JMS Business Overview

Table 94. JMS End-stage Renal Disease Therapeutics Product

Table 95. JMS Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 96. JMS Recent Development

Table 97. SB-KAWASUMI Company Details

Table 98. SB-KAWASUMI Business Overview

Table 99. SB-KAWASUMI End-stage Renal Disease Therapeutics Product

Table 100. SB-KAWASUMI Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 101. SB-KAWASUMI Recent Development

Table 102. Medica Group Company Details

Table 103. Medica Group Business Overview

Table 104. Medica Group End-stage Renal Disease Therapeutics Product

Table 105. Medica Group Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 106. Medica Group Recent Development

Table 107. Chongqing Shanwaishan Company Details

Table 108. Chongqing Shanwaishan Business Overview

Table 109. Chongqing Shanwaishan End-stage Renal Disease Therapeutics Product

Table 110. Chongqing Shanwaishan Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 111. Chongqing Shanwaishan Recent Development

Table 112. Amgen Company Details

Table 113. Amgen Business Overview

Table 114. Amgen End-stage Renal Disease Therapeutics Product

Table 115. Amgen Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 116. Amgen Recent Development

Table 117. Deltanoid Company Details

Table 118. Deltanoid Business Overview

Table 119. Deltanoid End-stage Renal Disease Therapeutics Product

Table 120. Deltanoid Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 121. Deltanoid Recent Development

Table 122. AbbVie Company Details

Table 123. AbbVie Business Overview

Table 124. AbbVie End-stage Renal Disease Therapeutics Product

Table 125. AbbVie Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 126. AbbVie Recent Development

Table 127. Sanofi Company Details

Table 128. Sanofi Business Overview

Table 129. Sanofi End-stage Renal Disease Therapeutics Product

Table 130. Sanofi Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 131. Sanofi Recent Development

Table 132. Ardelyx Company Details

Table 133. Ardelyx Business Overview

Table 134. Ardelyx End-stage Renal Disease Therapeutics Product

Table 135. Ardelyx Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 136. Ardelyx Recent Development

Table 137. AstraZeneca Company Details

Table 138. AstraZeneca Business Overview

Table 139. AstraZeneca End-stage Renal Disease Therapeutics Product

Table 140. AstraZeneca Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 141. AstraZeneca Recent Development

Table 142. Kyowa Hakko Kirin Company Details

Table 143. Kyowa Hakko Kirin Business Overview

Table 144. Kyowa Hakko Kirin End-stage Renal Disease Therapeutics Product

Table 145. Kyowa Hakko Kirin Revenue in End-stage Renal Disease Therapeutics Business (2019-2024) & (US$ Million)

Table 146. Kyowa Hakko Kirin Recent Development

Table 147. Research Programs/Design for This Report

Table 148. Key Data Information from Secondary Sources

Table 149. Key Data Information from Primary Sources

Table 150. Authors List of This Report

List of Figures

Figure 1. End-stage Renal Disease Therapeutics Picture

Figure 2. Global End-stage Renal Disease Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global End-stage Renal Disease Therapeutics Market Share by Type: 2023 VS 2030

Figure 4. Drugs Features

Figure 5. Device Features

Figure 6. Other Features

Figure 7. Global End-stage Renal Disease Therapeutics Market Size by Application (2024-2030) & (US$ Million)

Figure 8. Global End-stage Renal Disease Therapeutics Market Share by Application: 2023 VS 2030

Figure 9. Hospital Case Studies

Figure 10. Dialysis Center Case Studies

Figure 11. Other Case Studies

Figure 12. End-stage Renal Disease Therapeutics Report Years Considered

Figure 13. Global End-stage Renal Disease Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global End-stage Renal Disease Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global End-stage Renal Disease Therapeutics Market Share by Region: 2023 VS 2030

Figure 16. Global End-stage Renal Disease Therapeutics Market Share by Players in 2023

Figure 17. Global Top End-stage Renal Disease Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in End-stage Renal Disease Therapeutics as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by End-stage Renal Disease Therapeutics Revenue in 2023

Figure 19. North America End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America End-stage Renal Disease Therapeutics Market Share by Country (2019-2030)

Figure 21. United States End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe End-stage Renal Disease Therapeutics Market Share by Country (2019-2030)

Figure 25. Germany End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. France End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. U.K. End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Italy End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Russia End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Nordic Countries End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific End-stage Renal Disease Therapeutics Market Share by Region (2019-2030)

Figure 33. China End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Japan End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. South Korea End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Southeast Asia End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. India End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Australia End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America End-stage Renal Disease Therapeutics Market Share by Country (2019-2030)

Figure 41. Mexico End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Brazil End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa End-stage Renal Disease Therapeutics Market Share by Country (2019-2030)

Figure 45. Turkey End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Saudi Arabia End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. UAE End-stage Renal Disease Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Fresenius Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 49. Nikkiso Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 50. B.Braun Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 51. Baxter Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 52. Asahi Kasei Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 53. Nipro Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 54. Weigao Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 55. Toray Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 56. Medtronic Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 57. JMS Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 58. SB-KAWASUMI Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 59. Medica Group Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 60. Chongqing Shanwaishan Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 61. Amgen Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 62. Deltanoid Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 63. AbbVie Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 64. Sanofi Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 65. Ardelyx Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 66. AstraZeneca Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 67. Kyowa Hakko Kirin Revenue Growth Rate in End-stage Renal Disease Therapeutics Business (2019-2024)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

End Stage Renal Disease Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global End Stage Renal Disease ESRD Treatment Market Research Report 2025

Global End Stage Renal Disease ESRD Device Market Research Report 2024

Global End Stage Renal Disease Market Research Report 2024

Late Stage Chronic Kidney Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global End Stage Kidney Disease Market Research Report 2024

End Stage Renal Disease ESRD Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Renal Therapeutic Market Research Report 2025

Global Chronic Kidney Disease Medication Market Research Report 2024

Global CKD and ESRD Treatment Market Research Report 2025

Global Hemodialysis Drug Market Research Report 2024

Global End Stage Renal Disease Treatment Market Research Report 2025

Global Dialysis Drug Market Research Report 2024

Global Kidney Cancer Therapy Market Research Report 2024

Chronic Kidney Disease CKD Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Kidney Cancer Market Research Report 2025

Global Renal Diseases Drug Market Insights Forecast to 2030

Global Chronic Kidney Disease Treatment Market Research Report 2025

Global Chronic Kidney Disease CKD Treatment Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions